TY - JOUR
T1 - Application of 3D Bioprinting Technologies to the Management and Treatment of Diabetic Foot Ulcers
AU - Tan, Chew Teng
AU - Liang, Kun
AU - Ngo, Zong Heng
AU - Dube, Christabel
A2 - Lim, Chin Yan
N1 - Funding Information:
Funding: C.T.T. and K.L. are funded by Agency for Science, Technology and Research, Singapore, SERC Programmatic Grant A18A8b0059. C.Y.L. is funded by Agency for Science, Technology and Research, Singapore, SERC Programmatic Grant A18A8b0059 grant number and IAF-PP Program H17/01/a0/004.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/10/31
Y1 - 2020/10/31
N2 - Diabetes mellitus (DM) is a chronic metabolic disease with increasing prevalence worldwide. Diabetic foot ulcers (DFUs) are a serious complication of DM. It is estimated that 15–25% of DM patients develop DFU at least once in their lifetime. The lack of effective wound dressings and targeted therapy for DFUs often results in prolonged hospitalization and amputations. As the incidence of DM is projected to rise, the demand for specialized DFU wound management will continue to increase. Hence, it is of great interest to improve and develop effective DFU-specific wound dressings and therapies. In the last decade, 3D bioprinting technology has made a great contribution to the healthcare sector, with the development of personalized prosthetics, implants, and bioengineered tissues. In this review, we discuss the challenges faced in DFU wound management and how 3D bioprinting technology can be applied to advance current treatment methods, such as biomanufacturing of composite 3D human skin substitutes for skin grafting and the development of DFU-appropriate wound dressings. Future co-development of 3D bioprinting technologies with novel treatment approaches to mitigate DFU-specific pathophysiological challenges will be key to limiting the healthcare burden associated with the increasing prevalence of DM
AB - Diabetes mellitus (DM) is a chronic metabolic disease with increasing prevalence worldwide. Diabetic foot ulcers (DFUs) are a serious complication of DM. It is estimated that 15–25% of DM patients develop DFU at least once in their lifetime. The lack of effective wound dressings and targeted therapy for DFUs often results in prolonged hospitalization and amputations. As the incidence of DM is projected to rise, the demand for specialized DFU wound management will continue to increase. Hence, it is of great interest to improve and develop effective DFU-specific wound dressings and therapies. In the last decade, 3D bioprinting technology has made a great contribution to the healthcare sector, with the development of personalized prosthetics, implants, and bioengineered tissues. In this review, we discuss the challenges faced in DFU wound management and how 3D bioprinting technology can be applied to advance current treatment methods, such as biomanufacturing of composite 3D human skin substitutes for skin grafting and the development of DFU-appropriate wound dressings. Future co-development of 3D bioprinting technologies with novel treatment approaches to mitigate DFU-specific pathophysiological challenges will be key to limiting the healthcare burden associated with the increasing prevalence of DM
KW - 3D bioprinting
KW - Diabetic foot ulcers
KW - Wound healing
UR - http://www.scopus.com/inward/record.url?scp=85094174599&partnerID=8YFLogxK
UR - https://www.research.manchester.ac.uk/portal/en/publications/application-of-3d-bioprinting-technologies-to-the-management-and-treatment-of-diabetic-foot-ulcers(dae68e11-e178-4f72-aab1-d904631f701e).html
U2 - 10.3390/biomedicines8100441
DO - 10.3390/biomedicines8100441
M3 - Review article
C2 - 33096771
SN - 2227-9059
VL - 8
SP - 1
EP - 19
JO - Biomedicines
JF - Biomedicines
IS - 10
M1 - 441
ER -
